Chinese biotech's mega drug-licensing deals with multinationals surge on cost savings
Advertisement
Many of these deals use a so-called newco structure, which combines traditional intellectual property
licensing with fundraising via a newly established corporate vehicle, said the Shanghai-based partners of San Francisco-based international law firm Morrison Foerster.
'Last year we saw at least seven newco deals,' managing partner Sun Chuan said. 'So far this year we have already identified five deals, and more are under discussion.'
The broader
trend of Chinese biotech firms licensing their intellectual property – as an alternative to raising funds by selling shares amid depressed valuations – was also continuing, with both the number of deals so far this year and their value exceeding the same period a year earlier, he said.
On CSPC, based in Shijiazhuang in northern China's Hebei province, said it was in talks with unnamed parties on licensing development and marketing rights for its drug candidates including a targeted cancer therapy.
Advertisement
Potential payments to CSPC on each candidate could add up to US$5 billion, the company said. CSPC shares surged as much as 12.3 per cent on Friday.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
South China Morning Post
an hour ago
- South China Morning Post
Labubu's soft power, Trump eyes autumn China trip: 7 US-China relations reads
We have selected seven of the most interesting and important news stories covering US-China relations from the past few weeks. If you would like to see more of our reporting, please consider subscribing 1. Trump eyes autumn China trip, but September visit off the table: sources Photo: AFP US President Donald Trump is keen to visit China but a September visit is not happening, according to sources, who said Beijing and Washington were working to secure a trip in October or November. Hurdles remain, but high-level officials 'share a consensus', sources familiar with the matter told the South China Morning Post. Read the full story here 2. Trump says Beijing making 'big steps' in controlling fentanyl Photo: AP US President Donald Trump said in July that Beijing is 'making big steps' in efforts to control the flow of fentanyl, an issue that the American leader has used to justify tariffs that he has slapped on imports from China. 'I think China has been helping out,' Trump told reporters in the Oval Office. Read the full story here 3. Has Apple been trapped by China? Not so fast, analysts say Photo: Shutterstock A new book contending that Apple went too far in consolidating its operations in China is prompting debate among analysts of the country – some of whom say the company may have had no realistic alternatives. 'If they were to have it to do over again, would they have done anything differently?' asked Meg Rithmire, a Harvard Business School professor.
South China Morning Post
4 hours ago
- South China Morning Post
‘How can we trust you?': China's state media calls on Nvidia to prove safety of H20 chip
The article, entitled 'How can we trust you, Nvidia', called on the US company to 'comply with requests and provide convincing proof of security' to help regain the trust of its Chinese customers. 'Guarding network security is as important as protecting national territory,' the article said, adding that China should never use 'sick chips'. The People's Daily, the official newspaper of the Central Committee of the Chinese Communist Party , cited examples of how cyberattacks and satellite network glitches have weighed down public services in Russia , including disruption of services at airlines and pharmacies. 'Nvidia does not have 'back doors' in our chips that would give anyone a remote way to access or control them,' an Nvidia representative wrote in an email to the South China Morning Post on Thursday night. Chinese state media's attention showed a pressure-cooker-like situation for Nvidia amid its efforts to remain a major supplier of AI chips to China, while abiding by the trade restrictions imposed by the US government on the mainland.
South China Morning Post
5 hours ago
- South China Morning Post
China rebukes protectionism after Trump's new tariff barrage, warns it will harm everyone
In the wake of US President Donald Trump's latest tariff blitz on dozens of economies, China has reiterated a stern warning against protectionism amid growing concern that it will 'harm the interests of all parties'. 'China's position against the arbitrary imposition of tariffs has been consistent and clear: there are no winners in tariff or trade wars,' Guo Jiakun, spokesman for the Ministry of Foreign Affairs, said at a press conference on Friday. Beijing's latest admonishment came after Trump, by executive order, imposed widespread tariffs targeting 69 trading partners, ranging from 10 to 41 per cent – including a 35 per cent duty on many goods from Canada and 39 per cent on Switzerland. Most of the tariffs are due to take effect over the next seven days. Meanwhile, most Asian economies will face a levy of 15 to 20 per cent, compared with the 20-40 per cent tariff range threatened in July. But exceptions include India at 25 per cent, and Laos and Myanmar at 40 per cent each. Taiwan will face a 20 per cent tariff. One analyst said the latest tariff rates came as a relief to smaller economies such as Cambodia and Bangladesh, which had faced threats of 36 and 35 per cent tariffs from Trump in July. Now, their adjusted tariffs are 19 per cent and 20 per cent, respectively. 'The new rates preclude the worst but are cold comfort,' said Alex Holmes, regional director of Asia at the Economist Intelligence Unit. 'They represent a big rise in trade barriers and leave plenty of questions unanswered.
